Inventor · disambiguated record
Robert A. Copeland
Also filed as: COPELAND ROBERT A
12 granted patents·9 pending applications·187 citations·filing 1998–2020
93Inventor score
Files withEPIZYME INC8BRISTOL MYERS SQUIBB PHARMA CO6BRISTOL MYERS SQUIBB CO4ACCENT THERAPEUTICS INC2COPELAND ROBERT A1
Top patents by PatentIndex Score
21 records- 0196US8691507B2Inhibitors of human EZH2 and methods of use thereofEPIZYME INC·Filed 2013·Granted Apr 8, 2014·40 cites·12 claims
- 0294US9333217B2Inhibitors of human EZH2, and methods of use thereofEPIZYME INC·Filed 2014·Granted May 10, 2016·23 cites·6 claims
- 0393US8895245B2Inhibitors of human EZH2 and methods of use thereofCOPELAND ROBERT A·Filed 2011·Granted Nov 25, 2014·42 cites·8 claims
- 0492US9949999B2Inhibitors of human EZH2, and methods of use thereofEPIZYME INC·Filed 2016·Granted Apr 24, 2018·10 cites·17 claims
- 0578US7223834B2Assays and peptide substrate for determining aggrecan degrading metallo protease activityBRISTOL MYERS SQUIBB PHARMA CO·Filed 2001·Granted May 29, 2007·3 cites·24 claims
- 0677US7049412B1Antibodies to aggrecan-degrading metalloprotease and diagnostic methods using sameBRISTOL MYERS SQUIBB PHARMA CO·Filed 2000·Granted May 23, 2006·3 cites·3 claims
- 0777US6844318B2Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic useBRISTOL MYERS SQUIBB PHARMA CO·Filed 2001·Granted Jan 18, 2005·18 cites·37 claims
- 0875US7314726B2Beta secretase exosite binding peptides and methods for identifying beta secretase modulatorsBRISTOL MYERS SQUIBB CO·Filed 2003·Granted Jan 1, 2008·6 cites·3 claims
- 0973US6521436B1Nucleic acids encoding aggrecan degrading metallo proteasesBRISTOL MYERS SQUIBB CO·Filed 2000·Granted Feb 18, 2003·6 cites·4 claims
- 1073US2020397812A1Inhibitors of human ezh2, and methods of use thereofEPIZYME INC·Filed 2020·Application pending·0 cites
- 1169US6451575B1Aggrecan degrading metallo proteasesBRISTOL MYERS SQUIBB PHARMA CO·Filed 1998·Granted Sep 17, 2002·20 cites·20 claims
- 1268US6326162B1Assays and peptide substrate for determining aggrecan degrading metallo protease activityBRISTOL MYERS SQUIBB PHARMA CO·Filed 1998·Granted Dec 4, 2001·14 cites·2 claims
- 1365US2020016162A1Inhibitors of human ezh2, and methods of use thereofEPIZYME INC·Filed 2019·Application pending·0 cites
- 1463US2018271892A1Inhibitors of human ezh2, and methods of use thereofEPIZYME INC·Filed 2018·Application pending·0 cites
- 1562US6753176B2Aggrecan degrading metallo proteasesBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Jun 22, 2004·2 cites·4 claims
- 1660US2018243315A1Inhibitors of human ezh2, and methods of use thereofEPIZYME INC·Filed 2017·Application pending·0 cites
- 1757US2007238136A1Assays and peptide substrate for determining aggrecan degrading metallo protease activityBRISTOL MYERS SQUIBB PHARMA CO·Filed 2007·Application pending·0 cites
- 1856US2017065600A1Inhibitors of human ezh2, and methods of use thereofEPIZYME INC·Filed 2016·Application pending·0 cites
- 1949US2023027361A1Mettl3 modulatorsACCENT THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2048US2022372040A1Mettl3 modulatorsACCENT THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2142US2007149763A1Beta secretase exosite binding peptides and methods for identifying beta secretase modulatorsBRISTOL MYERS SQUIBB CO·Filed 2007·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Robert A. Copeland files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →